CARTITUDE-1: Myeloma CAR T-Cell Therapy Produces Deep and Durable Responses – ASH Clinical News
CARTITUDE-1: Myeloma CAR T-Cell Therapy Produces Deep and Durable Responses – ASH Annual Meeting, Multiple Myeloma, On Location – ASH Clinical News
CARTITUDE-1: Myeloma CAR T-Cell Therapy Produces Deep and Durable Responses – ASH Annual Meeting, Multiple Myeloma, On Location – ASH Clinical News
Naseema Gangat, MBBS, is a professor of medicine in the Division of Hematology at Mayo Clinic in Rochester, Minnesota. In the last two decades, open-access…
Leah Lawrence is a freelance health writer and editor based in Delaware. Use of the direct oral anticoagulant (DOAC) apixaban was not superior to cardiac…
Mary Ellen Schneider is a medical journalist based in Setauket, New York. Ruemu E. Birhiray, MD, is a hematologist/oncologist and clinical investigator at Hematology Oncology…
Katie Robinson is a medical writer based in New York. Compared with placebo, a high dose of oral vitamin A given before a hematopoietic cell…
The U.S. Food and Drug Administration (FDA) accepted Pfizer’s Biologics License Application for marstacimab as treatment for hemophilia A or hemophilia B in patients without…
In the December 2023 issue of “You Make the Call,” Shruti Chaturvedi, MBBS, MS, discussed treatment options for a female patient presenting with a left…
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. The anti-BCMA belantamab mafodotin (belamaf), plus pomalidomide and dexamethasone (Pd), produced durable…
Jill Sederstrom is a journalist based in Kansas City. For decades, health systems across the country have been devoting significant resources to make the shift…
We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will…
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone (VRd) induction and…